A detailed history of Fieldpoint Private Securities, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Fieldpoint Private Securities, LLC holds 1,155 shares of BMRN stock, worth $73,284. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,155
Previous 1,158 0.26%
Holding current value
$73,284
Previous $89,000 7.87%
% of portfolio
0.03%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 05, 2022

SELL
$71.48 - $86.85 $214 - $260
-3 Reduced 0.26%
1,155 $96,000
Q1 2022

Apr 07, 2022

BUY
$74.28 - $92.69 $86,016 - $107,335
1,158 New
1,158 $89,000
Q3 2021

Nov 12, 2021

SELL
$74.77 - $85.47 $121,650 - $139,059
-1,627 Closed
0 $0
Q2 2021

Aug 12, 2021

SELL
$75.51 - $84.79 $20,236 - $22,723
-268 Reduced 14.14%
1,627 $125,000
Q1 2021

Apr 23, 2021

SELL
$74.73 - $90.69 $39,382 - $47,793
-527 Reduced 21.76%
1,895 $143,000
Q4 2020

Jan 28, 2021

SELL
$72.61 - $90.2 $26,793 - $33,283
-369 Reduced 13.22%
2,422 $212,000
Q3 2020

Oct 23, 2020

BUY
$71.87 - $131.03 $51,458 - $93,817
716 Added 34.51%
2,791 $212,000
Q2 2020

Aug 14, 2020

SELL
$79.55 - $124.22 $229,501 - $358,374
-2,885 Reduced 58.17%
2,075 $256,000
Q1 2020

May 11, 2020

BUY
$71.37 - $96.85 $16,557 - $22,469
232 Added 4.91%
4,960 $419,000
Q4 2019

Feb 10, 2020

BUY
$64.27 - $86.37 $92,227 - $123,940
1,435 Added 43.58%
4,728 $400,000
Q3 2019

Nov 07, 2019

BUY
$67.4 - $85.11 $60,660 - $76,599
900 Added 37.61%
3,293 $222,000
Q2 2019

Aug 14, 2019

SELL
$80.35 - $93.9 $24,506 - $28,639
-305 Reduced 11.3%
2,393 $205,000
Q1 2019

May 13, 2019

SELL
$84.2 - $98.62 $23,576 - $27,613
-280 Reduced 9.4%
2,698 $240,000
Q4 2018

Feb 11, 2019

BUY
$80.14 - $106.07 $238,656 - $315,876
2,978 New
2,978 $254,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Fieldpoint Private Securities, LLC Portfolio

Follow Fieldpoint Private Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fieldpoint Private Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fieldpoint Private Securities, LLC with notifications on news.